Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CT-P53 vs Ocrevus in Relapsing-remitting Multiple Sclerosis
NCT05906992Phase 3Recruiting
- Sponsor
- Celltrion
- Start
- Jan 2024
- Primary completion
- Feb 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of CT-P53 in relapsing-remitting multiple sclerosis (RRMS), sponsored by Celltrion. Started Jan 2024; status: recruiting.
02
Drugs
CT-P53
03
Conditions
relapsing-remitting multiple sclerosis (RRMS)
Beyond the preview
Go deeper on NCT05906992.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05906992.